Re:Search Institution Members

160 Results for Collaborations

Collaborations

The Dr. Benjamin Bande develops an enhanced platform for the quantitative measurement of species-specific
snake venom toxins in the plasma (or other biological samples obtained from) of snakebite patients.

The visiting fellow receives training in the use of a number of preparative and analytical protein
chemistry technology platforms including electrophoresis, HPLC, mass spectrometry and bioinformatics
processing. In addition he is trained in techniques related to antibody production, immunoassay
design, assembly, data acquisition and analysis.

The visiting fellow receives training/experience in the handling, recording, storage and reporting of
data; the preparation and submission of animal ethics approval applications; intellectual property
protection agreements; project costing and budgeting; scientific writing; biostatistical analysis and has the opportunity to gain experience in a range of other laboratory skills and techniques.

Dr. Martha Yahimbu was involved in several projects. The first was a program to evaluate compounds in in vitro assays using several new techniques that are currently running at our site. Part of her rotation was to utilize instruments available here to separate, purify, and identify chemical compounds. This also involved chiral separation techniques. Martha has gained experience in how the project team operates and the process for bringing a compound from a hot to lead optimization. She has spent time with our formulations group to learn how to optimize in vivo dosing of compounds. The computer aided drug discovery group was involved in her projects and she was exposed to the programs we use to model compounds at all stages of the projects. In collaboration with UCSD she has also tested select compounds from a library in several neglected tropical diseases.

Dr. Evelyn Lavu will use whole genome sequencing (WGS) to describe the molecular epidemiology of MDR-TB in Papua and NCD, PNG and establish the relatedness of NCD MDR types to the Daru outbreak strain.

She will also assess the performance of TB diagnostics in PNG and describe the characteristics and prevalence of drug-resistance of patients diagnosed at the national laboratory over a 5 year period. The findings will guide policy in changing the TB screening test from sputum which has been the main stay of diagnosis of TB in PNG and treatment guidelines for DR-TB.

The training aims to provide Dr. Vitus Alberto Nyigo with the necessary hi-tech skills for drug discovery from natural products starting with advanced techniques with automations for the separation of the active constituents and then identifications of active ingredients either in pure form or in a mixture- as well as the different methods to evaluate the components and how to develop phytochemical markers and compound profiles.

172 Results for Assets

Assets

NIH Internal Reference no E-006-1990/0-US-01; US Patent Application no 07/470,692; and E-006-1990/0-US-02; US Patent Application no 08/462,616 Chloroquine an approved drug and the most commonly used antimalarial agent and analogs such as primaquine have been shown to inhibit infectious HIV-1 production and thus its spread in infected individuals. Inhibition may occur via interference with the terminal glycosylation of the viral glycoproteins, which results in the production of noninfectious virus.
This application relates to immunogenic conjugates which elicit an immune response to Plasmodium proteins. This application claims conjugates that include at least one Plasmodium sexual stage surface protein covalently linked to at least one Plasmodium circumsporozoite protein (CSP) or an immunogenic portion of a CSP. Also claimed in the application are conjugates that include at least one sexual stage surface protein covalently linked to at least one immunogenic repeat derived from a Plasmodium CSP. The inventors' data shows that these conjugates also induced long-lasting antibody responses to each of their components, i.e. the vaccine candidates showed both transmission blocking activity and antibodies to the CSP (or portion thereof).
This invention comprises a number of novel anti-mycobacterial compositions, which offer to significantly improve the treatment of mycobacterial infection such as tuberculosis. These newly discovered anti-mycobacterial compounds, which are analogs of thiatetracosanoate, have been shown effective in the treatment of mycobacterial infections and are relatively nontoxic. They may be given alone or in combination with standard anti-mycobacterial drugs and are valuable as antiseptics as well as therapeutics.
DNA segments encoding the Duffy receptor of a Plasmodium parasite A useful protein in the development of a potential malaria vaccine has been developed by cloning the gene for the Duffy binding receptor of Plasmodium vivax, a human malaria. Duffy blood group determinants on human erythrocytes are known to be essential for invasion by both the P. vivax and P. knowlesi malaria strains. A candidate malaria vaccine could result from the use of antibodies to the recombinant Duffy receptor binding protein or the receptor protein itself functioning through competitive blocking therapy.
Pvs28, a vaccine candidate for blocking transmission of plasmodium vivax This invention relates to methods for preventing transmission using PVs28 polypeptide of malaria by eliciting an immune response against parasites responsible for the disease. The Pvs28 polypeptide which is isolated from Plasmodium vivax can be administered to a susceptible organism to prevent transmission of malaria. Claims in this application are drawn to the Pvs28 polypeptide, the nucleic acid molecule which encodes Pvs28, pharmaceutical compositions containing Pvs28, and methods of inducing an immune response against Pvs28.
Oligo- or poly Ci 1~2 -D-glucose-based vaccine for tuberculosis including pneumonia and all primary infections caused by Mycobacterium tuberculosis vaccine, synthetic or natural, that will induce poly a~1~2 -D-glucose antibodies with bactericidal activity against Mycobacterium tuberculosis. These antibodies by be achieved by a: parenteral administration of a vaccine containing a synthetic or a natural saccharide with poly a 1~2 -D-glucose or a structural related antigen. The oligo- or poly a 1~2 -D-glucose; as a natural or synthetic product, may be bound to a carried saccharide and then to a non-toxic non-host protein carrier by directly to a non-toxic non-host protein carrier to form a donjugate. The saccharide-based vaccines is planned for active immunization for prevention of tuberculosis and TIor preparation of immune antibodies as a therapy. The scope of the patent should be confined to this poly Ci 1~2 -D-glucose-based vaccine which is designed to confer specific preventative immunity to infection with Mycobacterium tuberculosis and to induce antibodies specific to poly a 1~2 -D-glucose for therapy of tuberculosis.